| Author/Editor | Pirnat, Edvard | |
| Title | Vpliv tiamazola na zgodnje in pozne učinke zdravljenja z 131I pri bolnikih z bazedovko | |
| Type | monografija | |
| Place | Ljubljana | |
| Publisher | Univerza v Ljubljani, Medicinska fakulteta | |
| Publication year | 2005 | |
| Volume | str. 60 | |
| Language | slo | |
| Abstract | Antithyroid drugs (methimazole or propilthiouracil) are usually used as the first line therapy for Graves' disease. Radioiodine (131I) is applied when treatment is not successful or when the disease recurs. In the literature opinions differ as to the early effects of 131I application on serum thyroid hormone concentrations. Some authors describe the increase of thyroid hormone concentrations and exacerbation of hyperthyroidism after 131I. Pretreatment with antithyroid drugs should prevent that exacerbation. Others believe thet exacerbation of hyperthyroidism to be caused by antithyroid drug withdrawal and not 131I application. In addition, several authors believe that the success of 131I therapy can be reduced by means of pretreatment with antithyroid drugs and recommend stopping treatment a few days before'3'I application. Our objectives were the following: 1. to determine the influence of 131I application on the serum thyroid hormone concentrations in patients with Graves' disease; 2. to establish a posibility of elevation of thyroid hormone concentrations after stopping methimazole therapy ; 3. to evaluate whether methimazole therapy untill 131I application reduces the success of 131I therapy; 4. to determine the effect of 131I therapy in patients with methimazole withdrawal seven days before 131I application as well as in patients without pretreatment. 187 patients with Graves' disease were included in our prospective randomized clinical study. They were divided into three groups. Patients in the first group received 131I without methimazole pretreatment; in the second group methimazole was discontinued seven days before131I application and the third group of patients received methimazole until the 131I application. All patients were treated with fixed activity 550 or 740 MBq of 131I relative to their goiter size. (Abstract truncated at 2000 characters). | |
| Descriptors | GRAVES' DISEASE IODINE RADIOISOTOPES METHIMAZOLE TRIIODOTHYRONINE THYROXINE THYROTROPIN RANDOMIZED CONTROLLED TRIALS |